Tokenization in Biopharma Licensing
How Tokenization can Transform Pharma Licensing and Royalty Financing The pharmaceutical and biotech industries face a critical...
The Rise of Synthetic Royalties and Royalty-Backed Debt in Europe
European Growth and Market Dynamics Royalty financing and synthetic royalties are reshaping biotech and pharma funding in...
CAR-T Cell Therapy: Evolution, Adoption, and the Road Ahead
As a life sciences focused valuation and advisory firm, we observe the transformative potential of Chimeric Antigen...
From Lab to Liquidity: Royalty and Milestone Monetization for Universities and...
From Lab to Liquidity: Royalty and Milestone Monetization for Universities and Inventors Universities, research institutes, and academic...
Step into the Future of Informed Decision-Making: How RIVAL Software Empowers...
Step into the Future of Informed Decision-Making: How RIVAL Software Empowers Pharma and Biotech In the high-stakes...
Understanding Synthetic Royalties: A Creative Twist on Drug Monetization
In the high-stakes world of pharmaceuticals, turning a promising molecule into a marketed drug is a marathon...
The Influence of Taxes on Deals in the Biotech and Pharma...
The Influence of Taxes on Deals in the Biotech and Pharma Industry: A Strategic Perspective for Optimizing...
Unlocking Intrinsic Value for BioPharma Companies: The Key to Smarter Investments
In the complex and rapidly advancing world of biopharma, understanding a company’s intrinsic value is crucial for...
Understanding Bucket vs Progressive Royalty Tiers in Pharma Licensing Deals
Mastering royalty structures in biotech and pharma licensing deals is critical for achieving the desired financial outcomes....